Article
Exposure to wild-type AAV drives distinct capsid immunity profiles in humans
22 Oct 2018
Abstract excerpt
Recombinant adeno-associated virus (AAV) vectors have been broadly adopted as a gene delivery tool in clinical trials, owing to their high efficiency of transduction of several host tissues and their low immunogenicity. However, a considerable proportion of the population is naturally exposed to the WT virus from which AAV vectors are derived, which leads to the acquisition of immunological memory that can...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
